Dr. Brian S. Kim is director of the Mark Lebwohl Center for Neuroinflammation and Sensation and Vice Chair of Research of the Kimberly and Eric J. Waldman Department of Dermatology at Icahn School of Medicine at Mount Sinai. Key discoveries from the laboratory he led at the Washington University School of Medicine in St. Louis include the first identification of group 2 innate lymphoid cells (ILC2s) in the skin of both mice and humans, and their role in the pathogenesis of atopic dermatitis (AD) or eczema. Most recently, he has discovered how the immune system directly regulates sensory neurons to modulate the sensation of itch and how natural killer (NK) cells may be used as an immunotherapy strategy for AD. These studies have revealed novel therapeutic strategies which have led to successful clinical trials for new drugs for AD. He has multiple patents pending that led to the formation of Nuogen Pharma, Inc. that is developing JAK inhibitors for chronic pruritus. Dr. Kim’s research on innate immunity and neuroimmune regulation of AD and itch has led to awards and funding from the National Institutes of Health, Doris Duke Charitable Foundation, American Skin Association, American Academy of Dermatology, American Society for Clinical Investigation, American Dermatological Association, and the International League of Dermatology Societies. Dr. Kim has a Master of Science in Translational Research from the University of Pennsylvania. He is a fellow of the American Academy of Dermatology.
Brian S. Kim
